- Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS – yardımcı araştırmacı
- Effıcacy and Safety of Ranibizumab for the Treatment of Choroidal Neovascularization due to Uncommon Cause: Twelve-Month Results of the MINERVA Study – yardımcı araştırmacı
- Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (OCTAVE) – yardımcı araştırmacı
Op. Dr.
Cem Alay
Göz Hastalıkları Uzmanı